Maxzide (Maxzide)

Trade Name : MAXZIDE

Mylan Pharmaceuticals Inc.

TABLET

Strength 7550 mg/1mg/1

Storage and handling for MAXZIDE

TRIAMTERENE; HYDROCHLOROTHIAZIDE Decreased Renal K+ Excretion [PE],Increased Diuresis [PE],Potassium-sparing Diuretic [EPC],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [CS]

Disclaimer

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Maxzide (Maxzide) which is also known as MAXZIDE and Manufactured by Mylan Pharmaceuticals Inc.. It is available in strength of 75; 50 mg/1; mg/1 per ml. Read more

Maxzide (Maxzide) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

About GNH

No data

MAXZIDE (triamterene and hydrochlorothiazide) combines triamterene, a potassium-conserving diuretic, with the natriuretic agent, hydrochlorothiazide.
Each MAXZIDE tablet contains:
Triamterene, USP ............................................................................... 75 mgHydrochlorothiazide, USP .................................................................. 50 mg
Each MAXZIDE-25 MG tablet contains:
Triamterene, USP ................................................................................ 37.5 mgHydrochlorothiazide, USP .................................................................. u00a025 mg
MAXZIDE and MAXZIDE-25 MG tablets for oral administration contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, D&C Yellow No. 10 Aluminum Lake, magnesium stearate, microcrystalline cellulose, powdered cellulose and sodium lauryl sulfate. MAXZIDE-25 MG tablets also contain FD&C Blue No. 1 Aluminum Lake.
Triamterene is 2,4,7-triamino-6-phenylpteridine. Triamterene is practically insoluble in water, benzene, chloroform, ether and dilute alkali hydroxides. It is soluble in formic acid and sparingly soluble in methoxyethanol. Triamterene is very slightly soluble in acetic acid, alcohol and dilute mineral acids. Its molecular weight is 253.27. Its structural formula is:
Hydrochlorothiazide is 6-chloro-3,4-dihydro-2-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is slightly soluble in water and freely soluble in sodium hydroxide solution, n-butylamine and dimethylformamide. It is sparingly soluble in methanol and insoluble in ether, chloroform and dilute mineral acids. Its molecular weight is 297.73. Its structural formula is:

MAXZIDE (triamterene and hydrochlorothiazide) is a diuretic, antihypertensive drug product, principally due to its hydrochlorothiazide component; the triamterene component of MAXZIDE reduces the excessive potassium loss which may occur with hydrochlorothiazide use.

This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.
MAXZIDE may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since MAXZIDE (triamterene and hydrochlorothiazide) may enhance the actions of these drugs, dosage adjustments may be necessary.
The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.

No data

No data

No data

Side effects observed in association with the use of MAXZIDE, other combination products containing triamterene/hydrochlorothiazide, and products containing triamterene or hydrochlorothiazide include the following:
Gastrointestinal:
Central Nervous System:
Cardiovascular:
Renal:
Hematologic:
Ophthalmic:
Hypersensitivity:
Other:
Whenever adverse reactions are moderate to severe, therapy should be reduced or withdrawn.
Altered Laboratory Findings:
Arrayn- Serum Electrolytes:
Arrayn- Creatinine, Blood Urea Nitrogen:
Arrayn- Glucose:
Arrayn- Serum Uric Acid, PBI and Calcium:
Arrayn- Other:

No specific data are available regarding MAXZIDE (triamterene and hydrochlorothiazide) overdosage in humans and no specific antidote is available.
Fluid and electrolyte imbalances are the most important concern. Excessive doses of the triamterene component may elicit hyperkalemia, dehydration, nausea, vomiting and weakness and possibly hypotension. Overdosing with hydrochlorothiazide has been associated with hypokalemia, hypochloremia, hyponatremia, dehydration, lethargy (may progress to coma) and gastrointestinal irritation. Treatment is symptomatic and supportive. Therapy with MAXZIDE (triamterene and hydrochlorothiazide) should be discontinued. Induce emesis or institute gastric lavage. Monitor serum electrolyte levels and fluid balance. Institute supportive measures as required to maintain hydration, electrolyte balance, respiratory, cardiovascular and renal function.

The usual dose of MAXZIDE-25 MG is one or two tablets daily, given as a single dose, with appropriate monitoring of serum potassium (see ). The usual dose of MAXZIDE is one tablet daily, with appropriate monitoring of serum potassium (see ). There is no experience with the use of more than one MAXZIDE tablet daily or more than two MAXZIDE-25 MG tablets daily. Clinical experience with the administration of two MAXZIDE-25 MG tablets daily in divided doses (rather than as a single dose) suggests an increased risk of electrolyte imbalance and renal dysfunction.
Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE (triamterene and hydrochlorothiazide) directly. Patients receiving 25 mg hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE-25 MG (37.5 mg triamterene/25 mg hydrochlorothiazide) directly.
In patients requiring hydrochlorothiazide therapy and in whom hypokalemia cannot be risked therapy may be initiated with MAXZIDE-25 MG. If an optimal blood pressure response is not obtained with MAXZIDE-25 MG, the dose should be increased to two MAXZIDE-25 MG tablets daily as a single dose, or one MAXZIDE tablet daily. If blood pressure still is not controlled, another antihypertensive agent may be added (see ).
Clinical studies have shown that patients taking less bioavailable formulations of triamterene and hydrochlorothiazide in daily doses of 25 mg to 50 mg hydrochlorothiazide and 50 mg to 100 mg triamterene may be safely changed to one MAXZIDE-25 MG tablet daily. All patients changed from less bioavailable formulations to MAXZIDE should be monitored clinically and for serum potassium after the transfer.

MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow, bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:
NDC 0378-0460-01bottles of 100 tablets
MAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green, bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows:
NDC 0378-0464-01bottles of 100 tablets
Store at 20u00ba to 25u00baC (68u00ba to 77u00baF). [See USP Controlled Room Temperature.]
Protect from light.
Dispense in a tight, light-resistant, child-resistant container.
Mylan Pharmaceuticals Inc.

NDC 0378-0464-01
Arrayn- (triamterene andn- hydrochlorothiaziden- tablets, USP)n- 37.5 mg/n- 25 mg
Rx only u00a0u00a0u00a0100 Tablets
Each tablet contains 37.5 mgof triamterene, USP and 25 mgof hydrochlorothiazide, USP.
Dispense in a tight, light-resistantcontainer as defined in the USPusing a child-resistant closure.
Keep container tightly closed.
Keep this and all medicationn- out of the reach of children.
Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F).n- [See USP Controlled Roomn- Temperature.]
Protect from light.
Usual Adult Dosage:
Mylan Pharmaceuticals Inc.
Mylan.com
RBK0464A2

NDC 0378-0460-01
Arrayn- (triamterene andn- hydrochlorothiaziden- tablets, USP)n- 75 mg/n- 50 mg
Rx only u00a0u00a0u00a0100 Tablets
Each tablet contains 75 mgof triamterene, USP and 50 mgof hydrochlorothiazide, USP.
Dispense in a tight, light-resistantcontainer as defined in the USPusing a child-resistant closure.
Keep container tightly closed.
Keep this and all medicationn- out of the reach of children.
Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F).n- [See USP Controlled Roomn- Temperature.]
Protect from light.
Usual Adult Dosage:
Mylan Pharmaceuticals Inc.
Mylan.com
RBK0460A2

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise